Protagonist Therapeutics - Stock Price History | PTGX

Historical daily share price chart and data for Protagonist Therapeutics since 2021 adjusted for splits. The latest closing stock price for Protagonist Therapeutics as of October 26, 2021 is 32.42.
  • The all-time high Protagonist Therapeutics stock closing price was 49.69 on September 01, 2021.
  • The Protagonist Therapeutics 52-week high stock price is 50.54, which is 55.9% above the current share price.
  • The Protagonist Therapeutics 52-week low stock price is 12.80, which is 60.5% below the current share price.
  • The average Protagonist Therapeutics stock price for the last 52 weeks is 31.21.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Protagonist Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 15.1514 6.9300 25.1300 5.4000 20.1600 185.96%
2019 10.6231 6.8900 16.5600 4.6900 7.0500 4.75%
2018 10.6858 21.1500 23.0800 5.9900 6.7300 -67.64%
2017 14.5929 21.1800 21.1800 8.2200 20.8000 -5.41%
2016 19.1580 11.7000 26.2400 10.4400 21.9900 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.542B $0.029B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86